Showing 2731-2740 of 5909 results for "".
- Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8
- Visible Genomics Launches DNA Age-Related Macular Degeneration Testinghttps://modernod.com/news/visible-genomics-launches-dna-age-related-macular-degeneration-testing/2478264/Visible Genomics, a Chicago-area genetics testing company, has announced the launch of a new noninvasive genetic eye test that the company says determines a patient’s likelihood of contracting age-related macular degeneration (AMD). While it’s estimated that up to 70% of AMD cases are due
- AGTC Provides Trial Design Update for its Phase 2/3 XLRP Clinical Trialhttps://modernod.com/news/agtc-provides-trial-design-update-for-its-phase-2-3-xlrp-clinical-trial/2478261/Applied Genetic Technologies Corporation provided additional information about the proposed design of the planned phase 2/3 trial for its X-linked retinitis pigmentosa (XLRP) clinical program, which is expected to commence in the first quarter of 2021, and new preliminary data on
- Zeiss Launches “Vision in County” Cataract Development Program in Shandong, Chinahttps://modernod.com/news/zeiss-launches-vision-in-county-cataract-development-program-in-shandong-china/2478256/The “Vision in County” Cataract Development Program by Zeiss was officially launched in Shandong, China on September 3, 2020. At the event, the first training base was established in the Affiliated Eye Hospital of
- Ocular Therapeutix Announces Resolution of FDA Warning Letter Related to ReSure Sealanthttps://modernod.com/news/ocular-therapeutix-announces-resolution-of-fda-warning-letter-related-to-resure-sealant/2478250/Ocular Therapeutix announced it has received a letter from the FDA, dated September 2, 2020, closing out the Warning Letter it received from the FDA on October 18, 2018 concerning ReSure Sealant. The violation cited in Warning Letter (CMS #564663) has been addressed and Ocular is committed to sus
- Quantel Medical Launches Mosar High-Definition Imaging System for for Easyrethttps://modernod.com/news/quantel-medical-lauches-mosar-high-definition-imaging-system-for-for-easyret/2478247/Quantel Medical announced the launch of Mosar, a high-definition imaging system, on its yellow laser Easyret. Mosar features an HD camera, a screen and computer, and enhances the retinal laser treatment procedu
- Nearly One Quarter of Chinese Children Hospitalized With COVID-19 Developed Eye Symptomshttps://modernod.com/news/nearly-one-quarter-of-chinese-children-hospitalized-with-covid-19-developed-eye-symptoms/2478244/Among Chinese children hospitalized for COVID-19, nearly a quarter developed ocular symptoms, a new study finds, Reuters reported. Most children developed eye symptoms later in the disease, but in nine, ocular manifestations were the first
- HHS Bids $250 Million Contract Meant to ‘Defeat Despair and Inspire Hope’ on Coronavirushttps://modernod.com/news/hhs-bids-250-million-contract-meant-to-defeat-despair-and-inspire-hope-on-coronavirus/2478236/As the presidential election fast approaches, the Department of Health and Human Services is bidding out a more than $250 million contract to a communications firm as it seeks to “defeat despair and inspire hope” about the coronavirus pandemic, according to a
- Nicox Completes Enrollment of the Adaptive Design Cohort of NCX 470 Mont Blanc Phase 3 Glaucoma Trialhttps://modernod.com/news/nicox-completes-enrollment-of-the-adaptive-design-cohort-of-ncx-470-mont-blanc-phase-3-glaucoma-trial/2478234/Nicox SA announced that it completed enrollment of the adaptive design patient cohort in its multicenter Mont Blanc phase 3 trial, evaluating NCX 470 ophthalmic solution vs. latanoprost ophthalmic solution 0.005% for the lowering of IOP in patients with open-angle glaucoma or ocular hypertension.
- Injectsense Receives Breakthrough Device Program Designation From FDA for IOP Monitoring Systemhttps://modernod.com/news/injectsense-receives-breakthrough-device-program-designation-from-fda-for-iop-monitoring-system/2478233/Injectsense announced it has received a breakthrough device program (BDP) designation from the FDA for its chronic continuous IOP monitoring system for glaucoma patients. The company’s IOP Connect system is based on a long-term implantable sensor, smaller than a grain of rice, that is delivered t